Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

Vaccine

Volumn 26, Issue 1, 2007, Pages 119-127

  de Bruijn, Iris ^a   Meyer, Ingo ^b   Gerez, Lisya ^a   Nauta, Jos ^a   Giezeman, Katinka ^a   Palache, Bram ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

^b Momentum Pharma Services   (Germany)

Author keywords

Adjuvant; Elderly; Influenza; Subunit; Vaccine; Virosome

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; TRIPLE VACCINE; VIROSOME VACCINE;

ABSCESS; ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; HEADACHE; HEAT; HUMAN; IMMUNOGENICITY; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; PRURITUS; PSOAS ABSCESS; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEROLOGY; SHIVERING; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; SWELLING; VACCINATION; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, VIROSOME;

EID: 36749096389     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.051     Document Type: Article

References (53)

1. Ginaldi L., De Martinis M., D'Ostilio A., Marini L., Loreto M.F., Corsi M.P., et al. The immune system in the elderly. I. Specific humoral immunity. Immunol Res 20 2 (1999) 101-108
2. McElhaney J.E. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 23 Suppl 1 (2005) S10-S25
3. Sprenger M.J.W., Mulder P.G.H., Beyer W.E.P., van Strik R., and Masurel N. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidem 22 2 (1993) 334-340
4. Barker W.H., and Mullooly J.P. Pneumonia and influenza death during epidemics/implications for prevention. Arch Intern Med 142 1 (1982) 85-89
5. Glezen W.P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 4 1 (1982) 25-44
6. Reichert T.A., Simonsen L., Sharma A., Pardo S.A., Fedson D.S., and Miller M.A. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol 160 5 (2004) 492-502
7. Fleming D.M., and Elliot A.J. The impact of influenza on the health and health care utilisation of elderly people. Vaccine 23 Suppl 1 (2005) S1-S9
8. Simonsen L., Fukuda K., Schonberger L.B., and Cox N.J. The impact of influenza epidemics on hospitalizations. J Infect Dis 181 3 (2000) 831-837
9. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 292 11 (2004) 1333-1340
10. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., and Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123 7 (1995) 518-527
11. Nichol K.L., Wuorenma J., and Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158 16 (1998) 1769-1776
12. Webster R.G. Immunity to influenza in the elderly. Vaccine 18 16 (2000) 1686-1689
13. Nichol K.L., Nordin J., Mullooly J., Lask R., Fillbrandt K., and Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 348 14 (2003) 1322-1332
14. Simonsen L., Reichert T.A., Viboud C., Blackwelder W.C., Taylor R.J., and Miller M.A. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 165 3 (2005) 265-272
15. Simonsen L., Viboud C., and Taylor R. Influenza vaccination in elderly people. Lancet 366 9503 (2005) 2086
16. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., and Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366 9492 (2005) 1165-1174
17. WHO. Influenza vaccines. Weekly Epidem Rec 77 8 (2002) 229-240
18. Remarque E.J. Influenza vaccination in elderly people. Exp Gerontol 34 3 (1999) 445-452
19. Goodwin K., Viboud C., and Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24 8 (2006) 1159-1169
20. Goronzy J.J., Fulbright J.W., Crowson C.S., Poland G.A., O'Fallon W.M., and Weyand C.M. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 75 24 (2001) 12182
21. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol. 37 2-3 (2002) 427-439
22. Kemble G., and Greenberg H. Novel generations of influenza vaccines. Vaccine 21 16 (2003) 1789-1795
23. Cryz S.J., Que J.U., and Gluck R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 14 14 (1996) 1381-1383
24. Huckriede A., Bungener L., ter Veer W., Holtrop M., Daemen T., Palache A.M., et al. Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 21 9-10 (2003) 925-931
25. Daemen T., Bungener L., Huckriede A., and Wilschut J. Virosomes as an antigen delivery system. J Liposome Res 10 4 (2000) 329-338
26. Bungener L., Huckriede A., de Mare A., Vries-Idema J., Wilschut J., and Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23 10 (2005) 1232-1241
27. Valensi J.P.M., Carlson J.R., and van Nest G.A. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 153 9 (1994) 4029-4039
28. Minutello M., Senatore F., Cecchinelli G., Bianchi M., Andreani T., Podda A., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17 2 (1999) 99-104
29. De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17 23-24 (1999) 3094-3101
30. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19 17-19 (2001) 2673-2680
31. Baldo V., Menegon T., Bonello C., Floreani A., Trivello R., and Collaborative G. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19 25-26 (2001) 3472-3475
32. Gasparini R., Pozzi T., Montomoli E., Fragapane E., Senatore F., Minutello M., et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 17 2 (2001) 135-140
33. Banzhoff A., Nacci P., and Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 49 3 (2003) 177-184
34. Pregliasco F., Mensi C., Serpilli W., Speccher L., Masella P., and Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano) 13 1 (2001) 38-43
35. Squarcione S., Sgricia S., Biasio L.R., and Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21 11-12 (2003) 1268-1274
36. Ruf B.R., Colberg K., Frick M., and Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 32 4 (2004) 191-198
37. WHO. Recommanded composition of influenza virus vaccines for use in the 2005 influenza season. Weekly Epidem Rec 41 79 (2004) 369-376
38. Palmer DF, Dowdle WR, Coleman MT, Schild GC. Advanced laboratory techniques for influenza diagnosis. U.S. Dept. Health Edu. Welfare, P.H.S. Atlanta; 1975; Part 2, Hemagglutination Inhibition Test. p. 25-62.
39. http://www.meddramsso.com/MSSOWeb/index.htm. 2007. (GENERIC) Ref Type: Electronic Citation.
40. European Medicines Evaluation Agency. Note for guidance on harmonisation of requirements for influenza vaccines. Doc.Ref.CPMP/BWP/214/96. 1997. (GENERIC) Ref Type: Generic.
41. Zangwill K.M., Droge J., Mendelman P., Marcy S.M., Partridge S., Chiu C.Y., et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 20 8 (2001) 740-746
42. Nolan T., Lee M.S., Cordova J.M., Cho I., Walker R.E., August M.J., et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 21 11-12 (2003) 1224-1231
43. ICH guideline E9 (Statistical Principles for Clinical Trials). Note for Guidance on Statistical Principles for Clinical Trials. CPMP/ICH/363/96. 1998. (GENERIC) Ref Type: Generic.
44. FDA. Guidance for Industry: Clinical Data Needed to Support the Licensure of Trivalent Inactivated Influenza Vaccines - draft guidance. US Federal Register 2006; 71 (47 (Docket No. 2006D-0083)): 12367.
45. Diggle L., Deeks J.J., and Pollard A.J. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. BMJ 333 7568 (2006) 571
46. Baumgarth N., and Kelso A. Functionally distinct T cells in three compartments of the respiratory tract after influenza virus infection. Eur J Immunol 26 (1996) 2189-2197
47. Graham M.B., Braciale V.L., and Braciale T.J. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 180 4 (1994) 1273-1282
48. Johnson B.J., Costelloe E.O., Fitzpatrick D.R., Haanen J.B., Schumacher T.N., Brown L.E., et al. Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci USA 100 5 (2003) 2657-2662
49. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176 10 (2006) 6333-6339
50. Doherty P.C., Topham D.J., Tripp R.A., Cardin R.D., Brooks J.W., and Stevenson P.G. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 15 (1997) 9105-9117
51. Martin J.T. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 25 2 (1997) 209-213
52. Iob A., Brianti G., Zamparo E., and Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 133 4 (2005) 687-693
53. ®) in elderly subjects. Vaccine 24 44-46 (2006) 6629-6631